FDA Approves Inavolisib with Palbociclib and Fulvestrant for Endocrine-Resistant, PIK3CA-mutated, HR-positive, HER2-negative Advanced Breast Cancer By Ogkologos - November 20, 2024 639 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the INAVO120 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Grants Traditional Approval to Encorafenib for mCRC with a BRAF V600E Mutation In Memory of Hernán Cortés-Funes: Former ESMO President and Pioneer in Medical Oncology Immune Pathways Help Identify Patients with Cancer and HIV Most Likely to Experience Reservoir Decay with Anti-PD1 Therapy MOST POPULAR Neoadjuvant Camrelizumab Plus Chemotherapy Demonstrate Superior pCR Compared to Chemotherapy Alone... July 29, 2024 Selumetinib Approved by FDA to Treat Children with NF1 April 14, 2020 Significant Benefits of Nivolumab Plus Cabozantinib Over Sunitinib in Previously Untreated... March 5, 2021 Fears breast cancer progress could stall due to COVID-19 backlog June 15, 2021 Load more HOT NEWS Teen Quarterback Scores 8 Touchdowns A Day After His Mom Dies... Wine Racks and the Mystery of Survival FDA Grants Accelerated Approval to Sevabertinib for Non-Squamous NSCLC A radical project: video game design meets cancer research
